Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 270 | 230 | 196 | 158 | 175 | 221 | 219 | 212 |
| Operating profit | €m | 40.3 | 32.6 | ||||||
| Net profit | €m | 137 | 93 | 49 | 1 | 26 | 75 | 56 | 41 |
| EPS reported | € | 4.30 | 3.26 | ||||||
| Operating cashflow per share | € | 3.09 | 3.59 | ||||||
| Capex per share | € | 0.54 | 0.64 | ||||||
| FCF per share | € | 2.54 | 2.95 | ||||||
| Free cash flow | €m | 43.8 | 51.1 | ||||||
| Net debt | €m | -121 | -126 | ||||||
| Book value equity | €m | 252 | 251 | ||||||
| Book value per share | € | 14.63 | 14.47 | ||||||
| Number of shares | m | 17.21 | 17.34 | ||||||
| DPS (TTM paid) | € | 0.81 | 1.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 17.42 | 21.28 | ||||||
| P/B LTM | x | 5.12 | 4.93 | ||||||
| P/S LTM | x | 5.82 | 5.66 | ||||||
| P/FCF LTM | x | 29.46 | 24.20 | ||||||
| EV/EBITDA LTM | x | 27.34 | 25.79 | ||||||
| EV/Sales LTM | x | 5.97 | 5.08 | ||||||
| Earnings Yield LTM | % | 5.74% | 4.70% | ||||||
| FCF Yield | % | 3.39% | 4.13% | ||||||
| Quality | |||||||||
| ROE | % | 29.78% | 23.64% | ||||||
| ROIC | % | 12.83% | 10.62% | ||||||
| Operating margin | % | 18.19% | 14.93% | ||||||
| Gross margin | % | 94.46% | 90.57% | ||||||
| FCF/Sales | % | 19.76% | 23.37% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +188.59% | +36.97% | ||||||
| Sales Growth YoY | % | +26.61% | +15.52% | ||||||
| Net Income Growth YoY | % | +187.03% | +33.60% | ||||||
| FCF Growth | % | - | +3889.3% | ||||||
| Operating Profit Growth | % | +522.70% | +3.84% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.08% | 1.44% | ||||||
| Dividend Growth | % | - | +25.00% | ||||||
| Payout Ratio | % | 18.85% | 0.00% | ||||||
| FCF/Debt | x | 0.89 | 1.11 | ||||||
| Net Debt/EBITDA | x | 0.65 | 0.62 | ||||||
| EBIT/Net interest | x | 16.38 | 24.90 | ||||||
| Net debt/market cap | % | -9.36% | -10.17% | ||||||
| Net debt/Equity | x | -0.48 | -0.50 | ||||||
| Gross debt/equity | x | 0.20 | 0.18 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free